Denali Therapeutics (DNLI) Other Non-Current Liabilities (2017 - 2023)
Denali Therapeutics (DNLI) reported Other Non-Current Liabilities of $379000.0 for Q3 2023, little changed year-over-year from $379000.0 in Q3 2022, and little changed quarter-over-quarter from $379000.0 in Q2 2023.
Denali Therapeutics (DNLI) Other Non-Current Liabilities (2017 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has 7 years of Other Non-Current Liabilities data on file, last reported at $379000.0 in Q3 2023.
- Other Non-Current Liabilities for Q3 2023 came in at $379000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Sep 2023 was $379000.0 (changed 0.0% YoY), and the FY2022 annual result was $379000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities steadied at $379000.0 in Q3 2023 per DNLI's latest filing, from $379000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $701000.0 in Q4 2020 and troughed at $379000.0 in Q4 2019.
- A 5-year average of $451894.7 and a median of $379000.0 in 2019 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2019 and 2021: Other Non-Current Liabilities jumped 211.29% in 2019, then plunged 45.93% in 2021.
- A 5-year view of Other Non-Current Liabilities shows it stood at $379000.0 in 2019, then jumped by 84.96% to $701000.0 in 2020, then sank by 45.93% to $379000.0 in 2021, then changed by 0.0% to $379000.0 in 2022, then changed by 0.0% to $379000.0 in 2023.
- Business Quant data shows DNLI's Other Non-Current Liabilities at $379000.0 in Q3 2023, $379000.0 in Q2 2023, and $379000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 379,000.00 |
| Jun 30, 2023 | 379,000.00 |
| Mar 31, 2023 | 379,000.00 |
| Dec 31, 2022 | 379,000.00 |
| Sep 30, 2022 | 379,000.00 |
| Jun 30, 2022 | 379,000.00 |
| Mar 31, 2022 | 379,000.00 |
| Dec 31, 2021 | 379,000.00 |
| Sep 30, 2021 | 701,000.00 |
| Jun 30, 2021 | 701,000.00 |
| Mar 31, 2021 | 701,000.00 |
| Dec 31, 2020 | 701,000.00 |
| Sep 30, 2020 | 379,000.00 |
| Jun 30, 2020 | 379,000.00 |
| Mar 31, 2020 | 379,000.00 |
| Dec 31, 2019 | 379,000.00 |
| Sep 30, 2019 | 386,000.00 |
| Jun 30, 2019 | 408,000.00 |
| Mar 31, 2019 | 440,000.00 |
| Dec 31, 2018 | 471,000.00 |